Source explicitly identifies 2024-11-12 as the announcement or milestone date; pin uses this date. Investment period: By the end of 2026.[1]
AstraZeneca announced US$3.5 billion of U.S. capital investment through the end of 2026, including US$2 billion of new investment. The program spans research, biologics manufacturing, cell therapy and specialty manufacturing.
1.00